Showing 1991-2000 of 7286 results for "".
Enduring Success
https://practicaldermatology.com/topics/practice-management/enduring-success/20672/Make sure your practice does everything it can to satisfy and retain employees.Itch Be Gone
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/itch-be-gone/18524/Could botulinum toxins be the answer for non-histaminergic itch? Erin Gilbert, MD discusses her research in this area and results she's seen to date.Beyond SPF: Protecting the Skin
https://practicaldermatology.com/topics/skin-cancer-photoprotection/beyond-spf-protecting-the-skin-/18535/In addition to protecting the skin from sun damage, it's becoming increasingly important to consider pollution's role in skin aging. Arianne Shadi Kourosh, MD, and Rebecca Kazin, MD discuss the need for a well tailored regimen and what to look for in sun protection, barrier protection, cleaners, anEnbrel Gets Nod for Pediatric PsO; IL-33 Targeted in Itch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enbrel-gets-nod-for-pediatric-pso-il-33-targeted-in-itch/18562/FDA approved Amgen's Enbrel (etanercept) for chronic moderate to severe psoriasis in pediatric patients age 4 to 17. DermCheck App partners with anti-bullying groups Pacer and Not In My Town to help fight bullying and expand acne care. Researchers show that anti-IL-33 antibody reduces itch of poisonAllergan Acquires Vitae, PsA Day, Novan News
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-acquires-vitae-psa-day-novan-news/18572/Allergan is acquiring clinical-stage biotechnology company Vitae Pharmaceuticals for $21.00 per share, in cash, for a total transaction value of approximately $639 million. Novan has launched its initial public offering and is now listed on the NASDAQ. Celgene Corporation and the National PsoriasisImproving Outcomes with Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/improving-outcomes-with-fillers/18740/For the most optimal outcomes when injecting fillers, Dr. Galadari says there are three essential steps: choose the right patient, choose the right filler, and choose the right injection technique. He shares his favorite types of fillers for specific areas and discusses when and why he uses a cannulDoctors Betrayed by Traditional Financial Strategies, Part 2
https://practicaldermatology.com/topics/practice-management/doctors-betrayed-by-traditional-financial-strategies-part-2/20939/Helpful hints to avoid tax, investment, and insurance mistakes that can be made if you follow advice designed for tens of millions of average Americans.Decisions, Decisions...
https://practicaldermatology.com/topics/practice-management/decisions-decisions/20969/What it means to be a dermatologist is changing. Are you ready?Papa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouSRT100: Innovating Topical Radiation Therapy for Skin Cancers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/srt100-innovating-topical-radiation-therapy-for-skin-cancers/19041/The United States has become one of the chief areas of non-melanoma as well as melanoma skin cancer. One of the first treatments that was invented by dermatologists has been the use of radiation therapy for skin cancer. George Miller McKee, who is the father of many of the treatments of both melano